A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

Arthritis and Rheumatism

Volumn 54, Issue 12, 2006, Pages 3962-3970

  Hoyles, Rachel K ^a   Ellis, Ross W ^a   Wellsbury, Jessica ^a   Lees, Belinda ^a   Newlands, Pauline ^a   Goh, Nicole S L ^a   Roberts, Christopher ^b   Desai, Sujal ^c   Herrick, Ariane L ^d   McHugh, Neil J ^e   Foley, Noeleen M ^e   Pearson, Stanley B ^f   Emery, Paul ^f   Veale, Douglas J ^f   Denton, Christopher P ^g   Wells, Athol U ^a   Black, Carol M ^g   Du Bois, Roland M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d HOPE HOSPITAL   (United Kingdom)

^e ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^f LEEDS GENERAL INFIRMARY   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CARBON DIOXIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; PLACEBO; PREDNISOLONE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EVIDENCE BASED MEDICINE; FEMALE; FORCED EXPIRATORY VOLUME; HEMATURIA; HEMORRHAGIC CYSTITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG DIFFUSION; LUNG FIBROSIS; LUNG FUNCTION; MALE; MOOD DISORDER; MOUTH ULCER; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 33845643063     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22204     Document Type: Article

References (36)

1. LeRoy EC. Sentinel signs and symptoms of systemic sclerosis. Curr Opin Rheumatol 1989;1:499-504.
2. Owens GR, Fino GJ, Herbert D, Steen VD, Medsger TA Jr, Pennock BE, et al. Pulmonary function in progressive systemic sclerosis: comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983;84:546-50.
3. Wells AU, Cullinan P, Hansell DM, Rubens MB, Black CM, Newman-Taylor AJ, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994;149:1583-90.
4. Hamilton RF Jr, Parsley E, Holian A. Alveolar macrophages from systemic sclerosis patients: evidence for IL-4 mediated phenotype changes. Am J Physiol Lung Cell Mol Physiol 2004;286:L1202-9.
5. Wells AU, Lorimer S, Majumdar S, Harrison NK, Corrin B, Black CM, et al. Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. Eur Respir J 1995;8:266-71.
6. Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, Kronig G, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996;154:400-6.
7. Southcott AM, Jones KP, Li D, Majumdar S, Cambrey AD, Pantelidis P, et al. Interleukin-8: differential expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med 1995;151:1604-12.
8. Corrin B, Butcher D, McAnulty BJ, Dubois RM, Black CM, Laurent GJ, et al. Immunohistochemical localization of transforming growth factor-β 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994;24:145-150.
9. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161: 646-64.
10. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisolone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:838-44.
11. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994;37:729-35.
12. Steen VD, Lanz JK Jr, Conte C, Ownes GR, Medsger TA Jr. Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study. Arthritis Rheum 1994;37:1290-6.
13. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
14. Varai G, Earle L, Jiminez SA, Steiner RM, Varga J. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998;25: 1325-9.
15. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29:731-6.
16. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoviannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002;29:298-304.
17. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999;18:455-61.
18. Airo P, Danieli E, Parrinello G, Antonioli CM, Cavazzana I, Toniati P, et al. Intravenous cyclophosphamide therapy for systemic sclerosis: a single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004;22:573-8.
19. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulsed intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002;29:2371-8.
20. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998;41:1215-20.
21. Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004;23:306-9.
22. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, et al. Azathioprine combined with prednisolone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-6.
23. Winterbauer R. The treatment of idiopathic pulmonary fibrosis. Chest 1991;100:233-5.
24. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
25. Desai SR, Veeraraghavan S, Hansell DM, Nikolakopolou A, Goh NS, Nicholson AG, et al. CT features of lung disease in systemic sclerosis: comparison with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Radiology 2004;232:560-7.
26. Guidelines for the measurement of respiratory function: recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Respir Med 1994; 88:165-94.
27. American Thoracic Society. Surveillance for respiratory hazards in the occupational setting. Am Rev Respir Dis 1982;126:952-6.
28. Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003;62:146-50.
29. Antoniou KM, Nicholson AG, Dimadi M, Malagari K, Latsi P, Rapti A, et al. Long term clinical effects of IFNγ-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 2006. E-pub ahead of print.
30. Tashkin DP, Elashoff R, Clements PJ, Goldin R, Roth MD, Furst DE, et al, for the Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
31. Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003;15:748-55.
32. Strand V. Predictors and outcomes of scleroderma renal crisis: data from the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial [editorial]. Arthritis Rheum 2002; 46:2836-7.
33. Egan JJ, Nartinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005;60:270-3.
34. King TE Jr, Safrin S, Starko K, Brown KK, Noble PW, Reghu G, et al. Analyses of efficacy end points in a controlled trial of interferon-γ 1b for idiopathic pulmonary fibrosis. Chest 2005;127: 171-7.
35. Jegal Y, Kim D, Shim TS, Lim CM, Do Lee S, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:639-44.
36. Desai SR, Wells AU, Rubens MB, du Bois RM, Hansell DM. Traction bronchiectasis in cryptogenic fibrosing alveolitis: associated computed tomographic features and physiological significance. Eur Radiol 2003;13:1801-8.